Jing L. Marantz
Known title: CHIEF MEDICAL OFFICERCIK: 0001834528
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Transaction History
| SRRK | ▼ Sell | Open Market | 4,157 | $193K | 2/17/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 34,482 | $0 | 2/9/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 5,798 | $258K | 1/16/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 34,285 | $0 | 3/10/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 5,655 | $250K | 1/16/2025 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 6,375 | $55K | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,000 | $38K | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,100 | $82K | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 3,075 | $123K | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 200 | $8K | 11/25/2024 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 2,145 | $18K | 11/22/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,145 | $64K | 11/22/2024 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 2,105 | $18K | 11/11/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,105 | $63K | 11/11/2024 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 109,375 | $940K | 10/7/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 67,448 | $1.7M | 10/7/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,552 | $67K | 10/7/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 39,375 | $1.2M | 10/7/2024 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 | View on chart |
| SRRK | ▲ Buy | Grant | 72,855 | $0 | 2/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.